1. A 58-year-old man with heterozygous familial hypercholesterolemia is started on high-dose simvastatin 80 mg daily. Six weeks later he develops proximal leg weakness and his creatine kinase (CK) is 8,200 U/L. Pharmacogenomic testing reveals he carries the SLCO1B1 521T>C variant (rs4149056). Which of the following best explains the mechanism by which this variant increased his myopathy risk?
A) The variant upregulates CYP3A4 activity, accelerating simvastatin conversion to its active acid form and increasing tissue exposure
B) The variant reduces hepatic CYP2C9 expression, impairing simvastatin metabolism and prolonging its plasma half-life
C) The variant reduces activity of the OATP1B1 hepatic uptake transporter, decreasing hepatic statin uptake and increasing systemic statin exposure
D) The variant increases P-glycoprotein expression at the blood-brain barrier, redistributing simvastatin from the CNS to skeletal muscle
E) The variant impairs renal tubular secretion of simvastatin acid, reducing urinary elimination and raising plasma concentrations
ANSWER: C
Rationale:
The SLCO1B1 gene encodes OATP1B1 (organic anion-transporting polypeptide 1B1), a hepatic sinusoidal uptake transporter responsible for extracting statins from portal blood into hepatocytes — the site of both therapeutic action (HMG-CoA reductase inhibition) and first-pass metabolism. The 521T>C variant (rs4149056) reduces OATP1B1 transport activity, meaning less statin enters the liver and more remains in systemic circulation. This produces an unfavorable shift in the therapeutic index: hepatic exposure (where efficacy occurs) decreases while systemic and muscle exposure (where toxicity occurs) increases. The effect is most pronounced with simvastatin, which has high OATP1B1 dependence, and is the strongest known pharmacogenomic predictor of statin-associated muscle symptoms. Homozygous variant carriers face substantially elevated myopathy risk at standard simvastatin doses.
Option A: Option A is incorrect — the SLCO1B1 variant has no effect on CYP3A4 activity; CYP3A4 is involved in simvastatin metabolism but is a separate pharmacogenomic consideration.
Option B: Option B is incorrect — simvastatin is not a CYP2C9 substrate; CYP2C9 is relevant for fluvastatin and, to a lesser degree, rosuvastatin, not simvastatin.
Option D: Option D is incorrect — P-glycoprotein at the blood-brain barrier plays no meaningful role in simvastatin-associated myopathy, and the described redistribution mechanism does not occur.
Option E: Option E is incorrect — simvastatin and its active acid are primarily eliminated via hepatic metabolism and biliary excretion, not renal tubular secretion; renal elimination is not the relevant pharmacokinetic pathway here.
2. A 67-year-old woman who has been on atorvastatin 40 mg for three years develops progressive proximal muscle weakness and difficulty rising from a chair. Her CK is 4,800 U/L. Atorvastatin is discontinued, but eight weeks later her weakness has worsened rather than improved and her CK has risen to 7,200 U/L. Which of the following is the most appropriate next step in diagnosis?
A) Test for anti-HMGCR antibodies and refer for electromyography and muscle biopsy
B) Restart atorvastatin at half the dose and recheck CK in four weeks to confirm causality
C) Initiate a trial of coenzyme Q10 supplementation and recheck CK in six weeks
D) Test for anti-Jo-1 antibodies and initiate high-dose corticosteroids empirically without further workup
E) Reassure the patient that delayed resolution of statin-associated myopathy after drug discontinuation is common and requires no further evaluation
ANSWER: A
Rationale:
This presentation — proximal muscle weakness with markedly elevated CK that persists and worsens after statin discontinuation — is the clinical signature of statin-associated autoimmune myopathy (SAAM), also called immune-mediated necrotizing myopathy. Unlike the common statin-associated muscle symptoms that resolve within weeks of drug cessation, SAAM is driven by an immune-mediated mechanism that becomes self-sustaining after the statin trigger is removed. Anti-HMGCR (anti-3-hydroxy-3-methylglutaryl coenzyme A reductase) antibodies are the defining serological marker, present in approximately 60 to 70 percent of cases. The diagnostic workup includes anti-HMGCR antibody testing, electromyography (which typically shows an irritable myopathy pattern), and muscle biopsy (showing necrotizing myopathy with scattered necrotic and regenerating fibers but minimal inflammatory infiltrate — distinguishing it from polymyositis). Treatment requires immunosuppressive therapy: corticosteroids, methotrexate, azathioprine, or intravenous immunoglobulin. Statin cessation alone is insufficient.
Option B: Option B is incorrect and dangerous — restarting the offending statin in a patient with worsening immune-mediated myopathy would be expected to perpetuate or worsen the autoimmune process and is contraindicated.
Option C: Option C is incorrect — coenzyme Q10 supplementation has not been shown to benefit SAAM; it has been proposed for common SAMS but without robust evidence, and it has no role in immune-mediated disease.
Option D: Option D is incorrect in its approach — anti-Jo-1 antibodies are associated with antisynthetase syndrome (an inflammatory myopathy not related to statin exposure), and empirical corticosteroids without diagnostic confirmation is not appropriate initial management; the serological and biopsy workup should precede immunosuppression to confirm the diagnosis.
Option E: Option E is incorrect and potentially harmful — the clinical course described (worsening after discontinuation) is the opposite of benign delayed resolution and must not be attributed to common SAMS; failure to diagnose SAAM leads to progressive, severe, and potentially irreversible muscle damage.
3. A 54-year-old man is newly started on rosuvastatin 20 mg for primary prevention of atherosclerotic cardiovascular disease (ASCVD). His baseline alanine aminotransferase (ALT) is normal. He asks whether he needs regular blood tests to check his liver. Which of the following most accurately reflects current evidence-based practice regarding liver function monitoring during statin therapy?
A) ALT should be checked every three months for the first year, then annually thereafter, because delayed hepatotoxicity may develop insidiously during the first year of therapy
B) ALT should be checked at one month and three months after initiation; if both results are normal, no further monitoring is needed
C) Liver function tests should be checked every six months indefinitely because statins carry an FDA black-box warning for hepatotoxicity requiring ongoing surveillance
D) Routine periodic liver function testing during statin therapy is not recommended; baseline measurement is reasonable, and repeat testing should be prompted by symptoms rather than performed on a fixed schedule
E) Liver function testing is unnecessary at any point because statins are completely free of hepatic effects and the FDA has withdrawn all liver-related label language
ANSWER: D
Rationale:
In 2012, the FDA revised statin prescribing labels to remove the prior recommendation for routine periodic liver function testing during statin therapy. The revision was based on the recognition that asymptomatic, self-limited ALT elevations occur in approximately 0.5 to 3 percent of statin-treated patients but do not predict progression to clinically meaningful liver injury or liver failure, and that routine monitoring was generating unnecessary statin discontinuation in patients who would have benefited from continued therapy. True statin-induced hepatotoxicity causing clinical liver disease is extremely rare. The current evidence-based standard is: a baseline aminotransferase measurement before starting therapy (reasonable to establish a reference point, especially in patients with risk factors for liver disease), and repeat testing only when prompted by symptoms — jaundice, right upper quadrant pain, unexplained fatigue — not on a fixed schedule in asymptomatic patients.
Option A: Option A is incorrect — this quarterly monitoring schedule reflects pre-2012 practice that the FDA has explicitly abandoned; there is no evidence that delayed hepatotoxicity requires scheduled interval surveillance.
Option B: Option B is incorrect — the one- and three-month check schedule is not a current FDA or guideline recommendation; it has no evidence basis for improving detection of clinically meaningful hepatic injury.
Option C: Option C is incorrect on two counts: statins do not carry an FDA black-box warning for hepatotoxicity, and no recommendation for indefinite six-month monitoring exists in current labeling or major guidelines.
Option E: Option E is incorrect — while routine monitoring is not recommended, the 2012 label revision did not eliminate all liver-related label language; it retained guidance on symptomatic monitoring and noted that statins should generally be avoided in patients with active liver disease or unexplained persistent aminotransferase elevations.
4. A 61-year-old man with mixed dyslipidemia on simvastatin 40 mg daily has persistently elevated triglycerides at 480 mg/dL despite dietary modification. His physician considers adding a fibrate. Which of the following statements most accurately describes the pharmacokinetic basis for preferring fenofibrate over gemfibrozil as the combination partner?
A) Fenofibrate is a potent CYP3A4 inhibitor that competitively displaces simvastatin from its metabolic pathway, paradoxically reducing simvastatin plasma levels and protecting against myopathy
B) Gemfibrozil inhibits both OATP1B1-mediated hepatic statin uptake and statin glucuronidation, substantially increasing systemic statin exposure; fenofibrate does not share these interactions to a clinically significant degree
C) Fenofibrate undergoes extensive renal elimination and therefore does not enter the hepatic sinusoidal space where statin-fibrate interactions occur, avoiding the interaction entirely
D) Gemfibrozil is a selective peroxisome proliferator-activated receptor alpha (PPARα) agonist with higher receptor affinity than fenofibrate, and this higher PPARα activity directly damages skeletal muscle mitochondria in combination with statin therapy
E) Fenofibrate is a prodrug that requires hepatic hydrolysis to its active acid form; the hydrolysis step competes with statin metabolism at shared esterase sites, reducing statin activation and lowering myopathy risk
ANSWER: B
Rationale:
The clinically important difference between gemfibrozil and fenofibrate as statin combination partners lies in their pharmacokinetic interactions with statin elimination pathways. Gemfibrozil inhibits OATP1B1 (organic anion-transporting polypeptide 1B1) — the hepatic uptake transporter that extracts statins from portal blood into hepatocytes — and also inhibits the glucuronidation pathway (via UGT [UDP-glucuronosyltransferase] isoforms) by which statin acids are conjugated for biliary elimination. Both mechanisms increase systemic statin exposure substantially, raising myopathy risk. The combination of gemfibrozil and cerivastatin was associated with an unacceptably high rate of fatal rhabdomyolysis, leading to cerivastatin's market withdrawal in 2001, and the interaction applies to currently marketed statins as well. Fenofibrate does not inhibit OATP1B1 or statin glucuronidation to a clinically meaningful degree, making it the preferred fibrate when a statin-fibrate combination is clinically necessary. When a statin-fibrate combination must be used, fenofibrate is preferred, the lowest effective statin dose should be employed, and patients should be counseled to report muscle symptoms promptly.
Option A: Option A is incorrect — fenofibrate is not a CYP3A4 inhibitor and does not displace simvastatin from its metabolic pathway; the description is pharmacologically fictitious.
Option C: Option C is incorrect — the basis for fenofibrate safety is not renal elimination or anatomical separation from the hepatic sinusoidal space; fenofibrate is processed hepatically but simply does not inhibit the relevant statin transporters and conjugation enzymes.
Option D: Option D is incorrect — direct PPARα-mediated mitochondrial muscle toxicity is not the mechanism of gemfibrozil-statin interaction; the risk is pharmacokinetic, not pharmacodynamic, in origin.
Option E: Option E is incorrect — fenofibrate is indeed a prodrug (fenofibric acid is the active moiety), but the described competition at shared esterase sites is not accurate; esterase competition is not the pharmacological basis for fenofibrate's relatively favorable interaction profile.
5. A 72-year-old woman on simvastatin 40 mg and amiodarone presents with severe diffuse muscle pain, dark urine, and weakness so profound she cannot stand without assistance. Her CK is 68,000 U/L, creatinine has risen from her baseline of 0.9 to 3.2 mg/dL, and urinalysis shows large blood on dipstick with few red blood cells on microscopy. Which of the following correctly characterizes the severity classification of her presentation and its primary acute complication risk?
A) This presentation meets criteria for myopathy (CK greater than 10 times the upper limit of normal) with incidental renal impairment unlikely to be related to the muscle process
B) This presentation meets criteria for myalgia (symptomatic muscle pain without significant CK elevation), and the renal findings reflect a separate intercurrent process requiring independent evaluation
C) This presentation meets criteria for statin-associated autoimmune myopathy (SAAM) and requires urgent anti-HMGCR antibody testing before any other intervention
D) This presentation meets criteria for myopathy with CK elevation but does not yet fulfill rhabdomyolysis criteria because rhabdomyolysis requires CK greater than 100 times the upper limit of normal by current definition
E) This presentation meets criteria for rhabdomyolysis — CK markedly exceeding 40 times the upper limit of normal with myoglobinuria and acute kidney injury — representing the most severe form of statin-associated muscle toxicity
ANSWER: E
Rationale:
Rhabdomyolysis is defined by severe myopathy with CK elevation typically exceeding 40 times the upper limit of normal (ULN), accompanied by myoglobinuria and risk of acute kidney injury (AKI). This patient's CK of 68,000 U/L far exceeds this threshold, the dark urine with dipstick-positive blood but few red blood cells on microscopy is the classic presentation of myoglobinuria (myoglobin cross-reacts with the heme peroxidase on urine dipstick), and the rising creatinine confirms AKI — the primary acute complication and the cause of mortality in severe cases. Immediate management includes statin discontinuation, aggressive IV fluid resuscitation to protect the kidneys, and hospitalization. The amiodarone-simvastatin interaction is clinically significant: amiodarone inhibits CYP3A4 (cytochrome P450 3A4), which is the primary metabolic pathway for simvastatin, raising simvastatin plasma concentrations substantially and increasing myopathy and rhabdomyolysis risk — simvastatin doses above 20 mg are specifically cautioned against in combination with amiodarone.
Option A: Option A is incorrect — a CK of 68,000 U/L is not merely myopathy-level elevation; it substantially exceeds the rhabdomyolysis threshold, and the renal impairment with myoglobinuria is directly causally related to the muscle injury, not incidental.
Option B: Option B is incorrect — myalgia is symptomatic muscle pain without significant CK elevation; a CK of 68,000 U/L with systemic organ involvement is the opposite of this category.
Option C: Option C is incorrect — while SAAM is an important diagnosis, it presents with progressive weakness persisting after statin discontinuation and does not present acutely with myoglobinuria and AKI; the clinical context here is acute drug-interaction-mediated rhabdomyolysis, not immune-mediated disease, and anti-HMGCR testing is not the urgent priority.
Option D: Option D is incorrect — there is no 100× ULN threshold for rhabdomyolysis in clinical classification; the operative threshold is generally >40× ULN accompanied by systemic features including myoglobinuria and renal impairment, which this patient clearly fulfills.
6. A 49-year-old man with newly diagnosed hypercholesterolemia is prescribed simvastatin 20 mg. He asks whether it matters what time of day he takes it. Which of the following provides the most pharmacokinetically accurate counseling?
A) Evening dosing is preferred because hepatic cholesterol synthesis peaks between midnight and 2 a.m., and timing the peak plasma concentration of a short-half-life statin to coincide with maximal synthetic activity maximizes LDL-C lowering efficacy
B) Morning dosing is preferred because first-pass hepatic extraction of simvastatin is greatest in the morning due to diurnal variation in hepatic blood flow, increasing bioavailability of the active acid
C) Timing is irrelevant for simvastatin because its 20-hour half-life produces stable steady-state concentrations that are unaffected by dosing time
D) Evening dosing should be avoided because simvastatin undergoes extensive nocturnal renal elimination, and evening dosing increases the risk of crystalluria and tubular toxicity
E) Afternoon dosing is preferred because simvastatin requires a four-hour lag period before hepatic uptake begins, and afternoon dosing aligns peak uptake with the early-evening rise in cholesterol synthetic activity
ANSWER: A
Rationale:
Hepatic cholesterol synthesis follows a well-established circadian rhythm, peaking between midnight and 2 a.m. For short-half-life statins — simvastatin (half-life approximately 2 to 3 hours), lovastatin, pravastatin, and fluvastatin — timing peak plasma concentration to coincide with this nocturnal synthetic peak maximizes pharmacological inhibition of HMG-CoA reductase and produces the greatest LDL-C lowering effect. This is a clinically meaningful difference: studies have demonstrated that evening dosing of simvastatin produces greater LDL-C reduction than morning dosing at equivalent doses. This timing principle does not apply to long-half-life statins — atorvastatin (half-life 14 hours), rosuvastatin (half-life approximately 19 hours), and pitavastatin — which maintain effective plasma concentrations throughout the 24-hour dosing interval regardless of when they are taken; for these agents, morning dosing is equally effective and may improve adherence in patients with complex evening medication regimens. Counseling patients on the timing rationale improves adherence by providing a mechanistic reason for the dosing recommendation. option confuses the two.
Option B: Option B is incorrect — there is no clinically significant diurnal variation in hepatic blood flow that affects first-pass extraction of simvastatin; the bioavailability of simvastatin is not meaningfully higher in the morning.
Option C: Option C is incorrect — simvastatin's half-life is approximately 2 to 3 hours, not 20 hours; it is precisely the short half-life that makes dosing timing clinically relevant by determining when the plasma concentration peak occurs. Rosuvastatin has a half-life of approximately 19 hours; this
Option D: Option D is incorrect — simvastatin and its active acid are eliminated primarily via hepatic metabolism and biliary excretion; renal elimination is not the dominant pathway, and crystalluria is not a recognized statin toxicity.
Option E: Option E is incorrect — there is no four-hour lag period before hepatic uptake of simvastatin; absorption and first-pass hepatic extraction begin promptly after oral administration, and the described afternoon dosing rationale is pharmacologically fictitious.
7. A 68-year-old woman with established ASCVD (atherosclerotic cardiovascular disease) has failed trials of atorvastatin 40 mg, rosuvastatin 20 mg daily, and pravastatin 40 mg — each discontinued after four to six weeks due to reproducible proximal myalgia without significant CK elevation. She is reluctant to abandon statin therapy entirely. Which of the following represents the most pharmacologically rational next approach?
A) Switch to fluvastatin 80 mg extended-release daily, as extended-release formulations have been shown to eliminate statin-associated muscle symptoms by avoiding peak plasma concentrations
B) Initiate coenzyme Q10 (CoQ10) 400 mg daily as monotherapy and defer statin rechallenge for six months to allow mitochondrial recovery
C) Initiate rosuvastatin 5 mg every other day, exploiting its long half-life to provide meaningful LDL-C lowering with reduced daily muscle exposure, as part of a structured statin intolerance management protocol
D) Initiate simvastatin 10 mg daily because simvastatin has the lowest reported rate of SAMS (statin-associated muscle symptoms) across all available statins at low doses
E) Conclude that this patient has confirmed statin intolerance and proceed directly to PCSK9 inhibitor (proprotein convertase subtilisin/kexin type 9 inhibitor) monotherapy without any further statin rechallenge
ANSWER: C
Rationale:
Rosuvastatin is uniquely suited for alternate-day or twice-weekly dosing in statin-intolerant patients because of its long plasma half-life of approximately 19 hours — the longest of any currently marketed statin. This pharmacokinetic property allows meaningful hepatic HMG-CoA reductase inhibition to persist across a 48-hour dosing interval, producing LDL-C reductions of approximately 20 to 35 percent even with non-daily dosing, while substantially reducing the daily peak plasma concentration exposure that is associated with muscle symptom burden. This approach is a well-established step in the structured statin intolerance management protocol: the sequence proceeds from switching statin class → reducing dose → alternate-day or twice-weekly rosuvastatin → accepting partial statin intensity and combining with ezetimibe and/or a PCSK9 inhibitor. Complete statin avoidance is rarely necessary when this stepwise protocol is followed. This patient has failed daily dosing of three statins but has not yet tried the alternate-day approach — this step should be exhausted before concluding true intolerance.
Option A: Option A is incorrect — extended-release fluvastatin reduces peak plasma concentrations and may modestly reduce SAMS in some patients, but it is not established as eliminating muscle symptoms; it is a reasonable but lower-priority step compared to rosuvastatin alternate-day dosing, and the claim that extended-release formulations eliminate SAMS is overstated.
Option B: Option B is incorrect — CoQ10 supplementation lacks robust evidence of benefit in statin-associated muscle symptoms and has no role as monotherapy or as a prerequisite before statin rechallenge in clinical guidelines; the six-month deferral has no evidence basis.
Option D: Option D is incorrect — simvastatin does not have the lowest reported rate of SAMS; at equivalent intensity doses, lipophilic statins including simvastatin and atorvastatin have higher, not lower, rates of muscle symptoms compared to hydrophilic statins such as rosuvastatin and pravastatin, and the SLCO1B1 interaction is particularly relevant for simvastatin.
Option E: Option E is incorrect — proceeding directly to PCSK9 inhibitor monotherapy without exhausting statin rechallenge options, including alternate-day rosuvastatin, is premature; guidelines emphasize maximizing statin tolerance before moving entirely to non-statin LDL-C lowering, and the combination of any tolerated statin dose with ezetimibe and/or a PCSK9 inhibitor is preferred over PCSK9 inhibitor monotherapy.
8. A 71-year-old man on rosuvastatin 40 mg for five years develops progressive proximal weakness and CK of 5,400 U/L. Rosuvastatin is stopped but weakness continues to worsen over six weeks. Anti-HMGCR (anti-3-hydroxy-3-methylglutaryl coenzyme A reductase) antibodies return strongly positive. Muscle biopsy is performed. Which of the following best describes the expected histopathological finding that distinguishes this condition from inflammatory myopathies such as polymyositis?
A) Dense endomysial and perimysial CD8+ T-lymphocyte infiltrates surrounding and invading non-necrotic muscle fibers, with ragged-red fibers on modified Gomori trichrome staining
B) Perifascicular atrophy with complement deposition on capillaries and sparse perivascular CD4+ T-lymphocyte and B-lymphocyte infiltrates, consistent with dermatomyositis pattern
C) Granulomatous inflammation with multinucleated giant cells within muscle fascicles, consistent with sarcoid myopathy pattern
D) Scattered necrotic and regenerating muscle fibers with macrophage infiltration but minimal lymphocytic inflammatory infiltrate — a necrotizing pattern without the dense T-cell inflammation characteristic of polymyositis
E) Type II muscle fiber predominance with angular atrophic fibers and no necrosis or inflammatory infiltrate, consistent with a neurogenic rather than myopathic pattern
ANSWER: D
Rationale:
Statin-associated autoimmune myopathy (SAAM), also termed immune-mediated necrotizing myopathy (IMNM), produces a histopathological pattern that is diagnostically distinct from the classical inflammatory myopathies. Muscle biopsy shows scattered necrotic and regenerating fibers — reflecting ongoing muscle fiber death and attempted repair — with macrophage infiltration (macrophages clearing necrotic debris) but conspicuously minimal lymphocytic infiltrate. This absence of the dense T-cell inflammation that defines polymyositis is the key distinguishing histopathological feature. In polymyositis, CD8+ cytotoxic T-lymphocytes surround and invade non-necrotic muscle fibers — a pathognomonic finding absent in SAAM. The combination of anti-HMGCR seropositivity, clinical course persisting after statin discontinuation, and this necrotizing biopsy pattern without significant inflammatory infiltrate establishes the diagnosis. Treatment requires immunosuppression because the anti-HMGCR antibodies perpetuate the autoimmune attack on muscle despite drug removal.
Option A: Option A is incorrect — endomysial CD8+ T-lymphocyte invasion of non-necrotic fibers is the defining pattern of polymyositis, not SAAM; ragged-red fibers are a mitochondrial myopathy finding and are not characteristic of either condition.
Option B: Option B is incorrect — perifascicular atrophy with complement deposition on capillaries is the pathological hallmark of dermatomyositis, a distinct inflammatory myopathy associated with skin findings and a higher malignancy risk; it is unrelated to statin-induced immune-mediated disease.
Option C: Option C is incorrect — granulomatous inflammation with multinucleated giant cells is the pattern of sarcoid myopathy, a manifestation of systemic sarcoidosis; it is unrelated to statin-associated autoimmune pathology.
Option E: Option E is incorrect — type II fiber atrophy with angular fibers and no inflammation is a neurogenic pattern (denervation atrophy), consistent with motor neuron disease or peripheral neuropathy rather than a primary muscle disease; it does not describe any statin-associated muscle condition.
9. A 64-year-old man with stage 4 chronic kidney disease (CKD) — estimated glomerular filtration rate (eGFR) 22 mL/min/1.73m² — and established atherosclerotic cardiovascular disease is being considered for statin therapy. His nephrologist asks about appropriate statin selection and dosing in this context. Which of the following statements most accurately reflects evidence-based statin prescribing in advanced CKD?
A) Statins are contraindicated in CKD with eGFR below 30 mL/min/1.73m² because impaired renal clearance of all statins leads to drug accumulation and unacceptable myopathy risk regardless of dose
B) Statins reduce cardiovascular events in CKD patients with established ASCVD; agents with significant renal elimination such as rosuvastatin and pravastatin require dose adjustment in severe CKD, while predominantly hepatically eliminated statins such as atorvastatin do not require renal dose adjustment
C) Statins should be withheld in CKD until the patient reaches dialysis, at which point the cardiovascular mortality benefit becomes sufficiently large to justify the myopathy risk
D) All statins are equally safe in advanced CKD because the hepatic first-pass effect eliminates renal elimination as a pharmacokinetically relevant variable for all agents in this class
E) Rosuvastatin is absolutely contraindicated in CKD because it is exclusively renally eliminated, and any residual renal function below 60 mL/min/1.73m² results in toxic drug accumulation
ANSWER: B
Rationale:
Statins reduce cardiovascular morbidity and mortality in patients with CKD who have established ASCVD, and CKD itself is a cardiovascular risk-enhancing condition that strengthens the case for statin therapy. The key prescribing consideration in advanced CKD is statin pharmacokinetics: statins differ substantially in their routes of elimination. Atorvastatin is predominantly eliminated via hepatic metabolism and biliary excretion, with minimal renal clearance, and does not require dose adjustment even in severe CKD or dialysis — making it a frequently preferred agent in this population. Rosuvastatin and pravastatin have meaningful renal elimination components; rosuvastatin exposure increases approximately threefold in severe renal impairment, and doses above 10 mg are generally not recommended in patients with eGFR below 30 mL/min/1.73m². The SHARP (Study of Heart and Renal Protection) trial demonstrated that simvastatin 20 mg plus ezetimibe 10 mg reduced major atherosclerotic events in patients with CKD including those on dialysis, establishing the principle that lipid-lowering therapy benefits this population. Notably, initiating new statin therapy in patients already on dialysis who have not previously received a statin has shown less clear benefit in trials such as 4D and AURORA, but continuing established statin therapy through dialysis initiation remains appropriate.
Option A: Option A is incorrect — statins are not contraindicated in CKD with eGFR below 30; the concern is agent selection and dose adjustment, not a class-wide contraindication.
Option C: Option C is incorrect and reverses the clinical evidence — withholding statins until dialysis ignores the cardiovascular benefit in pre-dialysis CKD and is not consistent with guideline recommendations.
Option D: Option D is incorrect — statins differ substantially in renal elimination; the hepatic first-pass effect does not eliminate renal clearance as pharmacokinetically relevant for all agents, as rosuvastatin and pravastatin clearly demonstrate.
Option E: Option E is incorrect — rosuvastatin is not exclusively renally eliminated; it undergoes significant hepatic metabolism as well. The threshold for dose caution is eGFR below 30, not below 60, and the issue is dose adjustment rather than absolute contraindication.
10. A 32-year-old woman with familial hypercholesterolemia on atorvastatin 40 mg presents for a preconception counseling visit. She asks about continuing her statin during a planned pregnancy. Which of the following most accurately reflects the evidence and regulatory guidance on statin use in pregnancy?
A) Statins are safe in the first trimester because placental transfer is minimal for lipophilic agents; they should be discontinued only after the first trimester when organogenesis is complete
B) Statins may be continued throughout pregnancy in women with familial hypercholesterolemia because the cardiovascular risk of untreated hypercholesterolemia during pregnancy outweighs the teratogenic risk for this high-risk population
C) Statins should be substituted with bile acid sequestrants during pregnancy, which are considered equivalent in LDL-C lowering efficacy and have the same safety profile in pregnant women
D) Statin safety in pregnancy is well established for hydrophilic agents such as pravastatin and rosuvastatin, which do not cross the placenta; these may be continued while lipophilic statins are discontinued
E) Statins are contraindicated throughout pregnancy; atorvastatin should be discontinued before conception or immediately upon pregnancy recognition, and alternative non-pharmacological lipid management accepted for the duration of pregnancy
ANSWER: E
Rationale:
Statins are contraindicated in pregnancy. Cholesterol is an essential substrate for fetal steroidogenesis, neural development, and cell membrane synthesis, and HMG-CoA reductase inhibition during fetal development carries theoretical teratogenic risk based on this mechanism. Animal studies have demonstrated teratogenicity at doses producing human-equivalent plasma concentrations. Although the human epidemiological data are limited and do not conclusively establish a specific malformation pattern, the mechanistic concern and precautionary principle are sufficient to maintain the contraindication. FDA labeling for all statins carries a contraindication in pregnancy. In a planned pregnancy, statin therapy should be discontinued before conception — ideally at least one to three months before attempting to conceive — to allow washout. Upon pregnancy recognition in a patient on a statin, the drug should be discontinued immediately. The physiological hypercholesterolemia of normal pregnancy does not require pharmacological treatment; maternal cholesterol levels rise during pregnancy as part of the normal gestational lipid adaptation and this does not represent a therapeutic target in the absence of very severe hypertriglyceridemia posing pancreatitis risk.
Option A: Option A is incorrect — placental transfer of lipophilic statins is a concern, but the contraindication applies throughout pregnancy, not only after the first trimester; organogenesis does not represent a clean boundary for statin safety.
Option B: Option B is incorrect — familial hypercholesterolemia is not an exception to the pregnancy contraindication; while the long-term cardiovascular risk of untreated FH is significant, the appropriate management during pregnancy is to accept transient discontinuation rather than expose the fetus to a teratogenic drug.
Option C: Option C is incorrect — bile acid sequestrants are the preferred lipid-lowering agents during pregnancy when treatment is truly necessary, but they are not equivalent to statins in LDL-C lowering efficacy (they produce approximately 10 to 20 percent reduction versus 40 to 55 percent for high-intensity statins) and are not indicated for routine use in all pregnant women previously on statins.
Option D: Option D is incorrect — there is no evidence establishing that hydrophilic statins are safe in pregnancy or that they fail to cross the placenta in clinically meaningful amounts; the contraindication applies to the entire statin class and is not stratified by lipophilicity.
11. A medical student asks why cerivastatin is not available as a treatment option for hypercholesterolemia despite being an HMG-CoA reductase inhibitor. Which of the following most accurately explains the basis for cerivastatin's market withdrawal?
A) Cerivastatin had an unacceptably high rate of rhabdomyolysis — particularly when combined with gemfibrozil — that substantially exceeded the rate seen with other marketed statins, leading to voluntary market withdrawal in 2001
B) Cerivastatin was withdrawn because it produced unacceptable rates of new-onset type 2 diabetes at therapeutic doses, a complication not shared by other members of the statin class
C) Cerivastatin was withdrawn because it caused fulminant hepatic failure at a rate that exceeded the class rate, attributable to its unique hepatotoxic metabolite formed by CYP2C8-mediated biotransformation
D) Cerivastatin was withdrawn because post-marketing surveillance revealed it increased cardiovascular mortality rather than reducing it, reversing its anticipated therapeutic benefit
E) Cerivastatin was withdrawn because it was found to be a potent inhibitor of CYP3A4, producing life-threatening drug interactions with commonly prescribed medications including warfarin and cyclosporine
ANSWER: A
Rationale:
Cerivastatin was voluntarily withdrawn from the worldwide market in August 2001 because post-marketing surveillance identified an unacceptably high rate of rhabdomyolysis — fatal rhabdomyolysis occurred at a rate approximately 16 to 80 times higher than with other statins at the time of withdrawal. The interaction with gemfibrozil was particularly dangerous: gemfibrozil inhibits both OATP1B1-mediated hepatic cerivastatin uptake and the glucuronidation pathway responsible for cerivastatin elimination, dramatically increasing systemic cerivastatin exposure. A disproportionate number of rhabdomyolysis deaths occurred in patients on the cerivastatin-gemfibrozil combination. This interaction does not apply comparably to fenofibrate, which does not inhibit these pathways, and the cerivastatin rhabdomyolysis risk does not translate directly to currently marketed statins — though gemfibrozil remains cautioned against in combination with all statins. The cerivastatin withdrawal was a pivotal event that led to the current cautionary framework around statin-fibrate combinations and reinforced the clinical preference for fenofibrate over gemfibrozil as the combination partner when a fibrate is necessary.
Option B: Option B is incorrect — new-onset diabetes is a class effect of statins and is not the basis for cerivastatin's withdrawal; no statin has been withdrawn for this reason, as the cardiovascular benefit is considered to outweigh the diabetes risk in indicated populations.
Option C: Option C is incorrect — statin-associated fulminant hepatic failure is exceedingly rare across the class, and cerivastatin was not withdrawn for hepatotoxicity; the described CYP2C8 metabolite mechanism is not the pharmacological basis for cerivastatin's rhabdomyolysis risk.
Option D: Option D is incorrect — cerivastatin demonstrated expected LDL-C lowering in clinical trials and was not withdrawn for failure of cardiovascular benefit or increase in cardiovascular mortality.
Option E: Option E is incorrect — cerivastatin is not a significant CYP3A4 inhibitor; it was primarily metabolized by CYP2C8 and CYP3A4, not an inhibitor of CYP3A4, and warfarin or cyclosporine interactions were not the basis for its withdrawal.
12. A 58-year-old man with metabolic syndrome and a 10-year ASCVD risk of 18% is started on rosuvastatin 20 mg. At his six-month follow-up, his fasting glucose has risen from 108 mg/dL to 127 mg/dL and his HbA1c is 6.6%, meeting criteria for new-onset type 2 diabetes. He asks whether he should stop the statin. Which of the following most accurately reflects the appropriate clinical response?
A) Rosuvastatin should be immediately discontinued because statin-associated diabetes is a class-specific complication of rosuvastatin that does not occur with other statins, and switching to pravastatin will reverse the glycemic change
B) Rosuvastatin should be discontinued because the development of new-onset diabetes is an idiosyncratic hepatotoxic reaction to the drug that requires stopping and reporting to the FDA MedWatch system
C) Rosuvastatin should be continued because the cardiovascular mortality reduction from statin therapy in a patient with this risk profile substantially outweighs the risk attributable to a modest rise in plasma glucose; diabetes management should be initiated independently
D) Rosuvastatin should be replaced with ezetimibe 10 mg, which achieves equivalent LDL-C reduction without any diabetogenic effect, and is therefore the preferred agent in patients who develop statin-associated diabetes
E) Rosuvastatin should be discontinued and the patient reassured that his fasting glucose will return to pre-treatment levels within four to six weeks of drug cessation, as statin-associated diabetes is fully reversible upon withdrawal
ANSWER: C
Rationale:
Statin-associated new-onset diabetes is a recognized class effect that applies to all statins, with risk proportional to statin intensity — high-intensity statins (atorvastatin 40–80 mg, rosuvastatin 20–40 mg) carry a modestly higher diabetogenic risk than low- or moderate-intensity regimens. The absolute risk increase is approximately 0.1 to 0.2 new diabetes cases per 100 patient-years of statin therapy. Crucially, however, this modest incremental diabetes risk is substantially outweighed by the cardiovascular mortality and morbidity reduction in patients with the risk profile described — a 10-year ASCVD risk of 18% places this patient firmly in the category where high-intensity statin therapy is guideline-indicated. Patients who develop statin-associated diabetes were typically on the glycemic continuum toward diabetes before statin initiation (this patient's pre-treatment fasting glucose of 108 mg/dL represents impaired fasting glucose), and the statin appears to have accelerated rather than caused de novo diabetes. The appropriate response is to continue the statin and initiate diabetes management. The diabetes does not represent a reason to remove a proven cardiovascular risk-reduction intervention.
Option A: Option A is incorrect — statin-associated diabetes is a class effect, not unique to rosuvastatin; pravastatin has a modestly lower diabetogenic effect in some analyses, but switching statins does not reverse established diabetes and is not the appropriate clinical response.
Option B: Option B is incorrect — statin-associated diabetes is not a hepatotoxic reaction; it is a metabolic effect related to impaired insulin secretion and increased insulin resistance; the MedWatch framing is not appropriate for a known class effect at this level of severity.
Option D: Option D is incorrect — ezetimibe does not achieve equivalent LDL-C reduction to a high-intensity statin (ezetimibe produces approximately 15 to 20 percent LDL-C reduction versus 50 to 55 percent for rosuvastatin 20 mg); the cardiovascular outcomes data for ezetimibe monotherapy do not match the statin evidence base, and substituting ezetimibe for a statin in a high-risk patient is an inadequate replacement.
Option E: Option E is incorrect — statin-associated diabetes is not consistently or fully reversible upon drug withdrawal; the patient likely has underlying predisposition that the statin has unmasked, and simply stopping the statin does not reliably restore pre-treatment glucose levels or reduce the patient's intrinsic diabetes risk trajectory.
13. A 59-year-old man with alcohol-related cirrhosis classified as Child-Pugh B and a history of myocardial infarction is referred for cardiology follow-up. His current ALT is 52 U/L (upper limit of normal 40 U/L — 1.3× ULN). His cardiologist considers initiating atorvastatin for secondary prevention. Which of the following most accurately characterizes statin prescribing in this clinical context?
A) Statins are absolutely contraindicated in all patients with histologically confirmed cirrhosis regardless of Child-Pugh class because the hepatic metabolism of all statins is impaired sufficiently to cause toxic drug accumulation at any therapeutic dose
B) Statins are safe in any liver disease provided ALT remains below 10× ULN; the conventional 3× ULN threshold for caution is an outdated guideline that has been superseded by current hepatology practice
C) Statins are contraindicated in compensated cirrhosis because portal hypertension impairs hepatic arterial inflow, preventing adequate first-pass extraction and creating predictable dose-dependent hepatotoxicity
D) Statins are generally appropriate in compensated cirrhosis (Child-Pugh A–B) when ALT is below 3× ULN; the cardiovascular benefit should not be forfeited due to exaggerated hepatotoxicity concerns; decompensated cirrhosis (Child-Pugh C) represents a genuine contraindication
E) Statins should be withheld in all patients with cirrhosis and replaced with PCSK9 inhibitors, which are not hepatically metabolized and therefore carry no hepatic risk in this population
ANSWER: D
Rationale:
The clinical framework for statin use in liver disease is nuanced and frequently misapplied through excessive caution. Statins are generally appropriate in compensated chronic liver disease and compensated cirrhosis (Child-Pugh A–B) when ALT is below 3× ULN — the threshold that signals active hepatocellular injury requiring caution. This patient has Child-Pugh B cirrhosis with an ALT of only 1.3× ULN, placing him in the category where statin therapy for secondary prevention is clinically warranted. The cardiovascular benefit in established ASCVD is substantial, and forfeiting that benefit due to exaggerated hepatotoxicity concerns in a patient with compensated liver disease is a clinical error. True statin-induced clinical hepatotoxicity causing progressive liver injury is extremely rare. Statins should be avoided in active hepatitis with significantly elevated aminotransferases (greater than 3× ULN) and are contraindicated in decompensated cirrhosis (Child-Pugh C) due to the risk of hepatic decompensation. Pravastatin has been the most studied statin in cirrhosis given its minimal hepatic first-pass metabolism and limited CYP interaction profile. Notably, portal hypertension studies have suggested a hepatoprotective portal pressure-reducing effect of statins in cirrhosis through eNOS (endothelial nitric oxide synthase)-mediated vasodilation, though this remains investigational.
Option A: Option A is incorrect — a Child-Pugh class-blind absolute contraindication for all cirrhosis does not reflect current evidence or guideline practice; compensated cirrhosis with near-normal aminotransferases is not a contraindication to statin therapy.
Option B: Option B is incorrect — the 3× ULN threshold for aminotransferase caution is not outdated; it represents a clinically reasonable boundary beyond which the risk of active hepatocellular injury makes initiating or continuing statin therapy inadvisable pending investigation.
Option C: Option C is incorrect — portal hypertension does not impair hepatic arterial inflow to a degree that reliably impairs first-pass statin extraction; the hemodynamic changes of cirrhosis affect portal flow, not arterial inflow, and the clinical consequence is increased systemic statin bioavailability (due to reduced first-pass effect) rather than predictable dose-dependent hepatotoxicity.
Option E: Option E is incorrect — PCSK9 inhibitors are monoclonal antibodies cleared by proteolytic degradation rather than hepatic enzymatic metabolism, making hepatic disease less pharmacokinetically relevant, but this does not mean all cirrhotic patients should be automatically switched from statins to PCSK9 inhibitors; statins remain the evidence-based first-line LDL-C lowering therapy with the strongest cardiovascular outcomes data.
14. A 48-year-old man undergoes orthotopic heart transplantation for ischemic cardiomyopathy. His post-transplant baseline LDL-C is 88 mg/dL. His transplant cardiologist initiates pravastatin 20 mg within the first two weeks post-transplant. A colleague asks whether this is appropriate given the relatively low LDL-C. Which of the following most accurately explains the clinical rationale for early statin initiation in cardiac transplant recipients regardless of baseline LDL-C?
A) Pravastatin is initiated early post-transplant solely to prevent the hypercholesterolemia induced by calcineurin inhibitors such as cyclosporine, which uniformly raise LDL-C to levels exceeding 180 mg/dL within four weeks of transplantation
B) Early pravastatin initiation after cardiac transplantation reduces acute rejection episodes and improves one-year survival through immunomodulatory pleiotropic effects independent of LDL-C lowering — including reduced natural killer cell cytotoxicity and reduced MHC class II expression — not solely through lipid reduction
C) Pravastatin is initiated post-transplant because it is the only statin that does not interact with cyclosporine, making it the sole safe agent in this population; the dose is adjusted based on cyclosporine trough levels rather than LDL-C targets
D) Early pravastatin initiation is a class I guideline recommendation because transplant-associated accelerated coronary artery disease is caused entirely by LDL-C elevation, and the LDL-C target in transplant recipients is below 50 mg/dL, requiring immediate high-intensity therapy regardless of baseline
E) Pravastatin is initiated early post-transplant because transplant recipients are at high risk for statin-induced rhabdomyolysis from cyclosporine interaction, and pravastatin — having the shortest half-life of all statins — clears most rapidly if toxicity develops
ANSWER: B
Rationale:
The rationale for early statin initiation after cardiac transplantation is one of the clearest clinical demonstrations of statin pleiotropic benefits contributing independently to clinical outcomes beyond LDL-C lowering. Registry analyses and the Cardiac Transplant Research Database (COCPIT) trial demonstrated that pravastatin initiated early after cardiac transplantation — within the first weeks post-transplant — reduces acute rejection episodes and improves one-year survival. The mechanism is attributed substantially to immunomodulatory properties: statins reduce natural killer cell cytotoxicity, downregulate MHC class II (major histocompatibility complex class II) expression on antigen-presenting cells, modulate T-lymphocyte activation, and reduce pro-inflammatory cytokine production. These effects are independent of the degree of LDL-C lowering and occur at plasma concentrations achieved with standard clinical doses. This is why statin initiation is recommended regardless of baseline LDL-C in this population. The choice of pravastatin specifically in many transplant protocols also reflects its minimal CYP3A4 metabolism (reducing interaction with cyclosporine, which is a CYP3A4 inhibitor and can substantially raise plasma concentrations of CYP3A4-dependent statins).
Option A: Option A is incorrect — while calcineurin inhibitors including cyclosporine do promote hypercholesterolemia, not all recipients reach LDL-C of 180 mg/dL within four weeks, and the primary rationale for early statin initiation is immunomodulatory, not solely lipid-driven.
Option C: Option C is incorrect — pravastatin is preferred but is not the only statin used post-transplant; other statins including fluvastatin are used with attention to drug interactions; the claim that dosing is adjusted based on cyclosporine trough levels rather than LDL-C is incorrect in that the rationale for initiation is immunomodulatory, but dosing is not titrated to cyclosporine trough levels.
Option D: Option D is incorrect — while transplant-associated coronary artery disease (cardiac allograft vasculopathy) is a major long-term complication, its pathogenesis is predominantly immune-mediated rather than driven entirely by LDL-C; a below-50 mg/dL LDL-C target requiring immediate high-intensity therapy is not the stated guideline rationale for early post-transplant statin initiation.
Option E: Option E is incorrect — pravastatin does not have the shortest half-life of all statins (fluvastatin has a shorter half-life); and while the favorable CYP interaction profile of pravastatin is relevant, the primary basis for early initiation is immunomodulatory benefit, not rapid clearance in anticipated toxicity.
15. A 55-year-old woman is started on atorvastatin 40 mg. She has no muscle symptoms and no personal or family history of muscle disease. Her internist asks about the appropriate approach to CK (creatine kinase) monitoring during statin therapy. Which of the following most accurately reflects current evidence-based recommendations?
A) CK should be measured at baseline and at one, three, and six months after initiation, then annually, because subclinical myopathy detectable only by CK elevation frequently precedes symptomatic SAMS (statin-associated muscle symptoms) and early intervention prevents rhabdomyolysis
B) CK should be measured at baseline and after any dose increase because the dose-response relationship for statin myopathy is linear and dose increases carry a predictable increment in CK elevation that requires monitoring
C) CK measurement is unnecessary at any point, including baseline, because statin-associated muscle toxicity is entirely symptom-driven and CK elevation in asymptomatic patients has no clinical significance or management implications
D) CK should be measured monthly for the first six months of statin therapy regardless of symptoms, then biannually, with statin discontinuation recommended for any value exceeding the upper limit of normal
E) Baseline CK measurement is reasonable in patients at higher risk for muscle disease; routine periodic CK monitoring in asymptomatic patients during statin therapy is not recommended — testing should be triggered by the development of muscle symptoms
ANSWER: E
Rationale:
Current guidelines and expert consensus do not recommend routine periodic CK monitoring in asymptomatic patients on statin therapy. The clinical basis is straightforward: asymptomatic CK elevations are common in the general population (from exercise, physical labor, and other causes), do not reliably predict progression to symptomatic myopathy or rhabdomyolysis, and generate unnecessary patient anxiety and statin discontinuation without improving outcomes. CK testing during statin therapy should be prompted by the development of muscle symptoms — myalgia, proximal weakness, muscle cramping — at which point the result guides management decisions (mild elevation with tolerable symptoms versus elevation exceeding 10× ULN meeting myopathy criteria versus elevation exceeding 40× ULN meeting rhabdomyolysis criteria). Baseline CK measurement is clinically reasonable in patients at higher risk for muscle disease — those with prior muscle disease, a relevant family history, advanced age, hypothyroidism, renal or hepatic impairment, or planned combination with a potentially interacting drug — to establish a reference point. In a low-risk patient such as this one, baseline CK is optional.
Option A: Option A is incorrect — scheduled interval CK monitoring at one, three, and six months is not a current guideline recommendation; there is no evidence that routine surveillance CK measurement prevents rhabdomyolysis or improves clinical outcomes in asymptomatic patients.
Option B: Option B is incorrect — while dose increases do raise the probability of muscle symptoms, scheduled CK monitoring with every dose increase is not a guideline recommendation; the appropriate response to a dose increase is clinical surveillance for symptoms, not reflexive CK measurement.
Option C: Option C is incorrect in its absolute framing — while routine monitoring is not recommended, baseline CK in high-risk patients is reasonable and clinically useful; stating that CK measurement is unnecessary at any point is an overstatement that could lead to failure to establish a baseline in genuinely high-risk patients.
Option D: Option D is incorrect — monthly monitoring followed by biannual monitoring, with statin discontinuation for any elevation above the ULN, is not current practice; this approach would result in widespread inappropriate statin discontinuation given the prevalence of minor, clinically insignificant CK elevations in the general population.
16. A 63-year-old woman with a 10-year ASCVD risk of 22% reports that she has "tried statins before" and "they all cause muscle pain." Chart review reveals she took atorvastatin 40 mg for three weeks before self-discontinuing due to diffuse myalgia; no CK was measured and no rechallenge was attempted. Her cardiologist wants to optimize her lipid management. Which of the following represents the most appropriate and evidence-based next step?
A) Initiate a structured statin intolerance rechallenge protocol: switch to a different statin at a lower dose, confirm symptom reproducibility across multiple agents before concluding true intolerance, and progress through a stepped sequence of dose reduction and alternate-day rosuvastatin before abandoning statin therapy
B) Accept the patient's self-report of statin intolerance as definitive and initiate bempedoic acid monotherapy, which is specifically FDA-indicated for statin-intolerant patients and achieves equivalent cardiovascular outcomes to statin therapy
C) Order serum anti-HMGCR antibody testing before any rechallenge because the described presentation is most consistent with statin-associated autoimmune myopathy, and rechallenge is contraindicated until SAAM has been excluded serologically
D) Accept the patient's self-report and initiate PCSK9 inhibitor monotherapy, as PCSK9 inhibitors are the only agents demonstrated in randomized trials to reduce ASCVD events in statin-intolerant patients and are now first-line for this indication
E) Rechallenge with atorvastatin 40 mg — the same drug and dose at which symptoms occurred — to confirm true statin intolerance before considering alternative agents, because guideline protocols require rechallenge with the identical agent before switching
ANSWER: A
Rationale:
A single three-week course of one statin at a high dose, self-discontinued without CK measurement and without formal rechallenge, does not constitute confirmed statin intolerance. The nocebo effect — symptom development driven by expectation of harm rather than pharmacological toxicity — accounts for a substantial proportion of reported statin-associated muscle symptoms, particularly in patients aware of statin myopathy risk from media or social sources. The appropriate approach is a structured rechallenge protocol: switch to a different statin (different chemical structure and lipophilicity profile may be better tolerated), use the lowest effective dose, confirm that symptoms recur with the new agent before attributing them to the statin class, and if daily dosing is not tolerated, proceed to alternate-day rosuvastatin. Complete statin avoidance is rarely necessary when this protocol is followed rigorously. The step sequence is: switch statin → reduce dose → alternate-day rosuvastatin → accept maximum tolerated statin dose and add ezetimibe and/or PCSK9 inhibitor for additional LDL-C reduction. Concluding statin intolerance after a single inadequate trial deprives a high-risk patient of the most evidence-robust cardiovascular risk-reduction therapy available.
Option B: Option B is incorrect — bempedoic acid is an ATP citrate lyase inhibitor approved for use in statin-intolerant patients and does reduce LDL-C, but it has not demonstrated equivalent cardiovascular outcomes to statin therapy; CLEAR Outcomes trial showed benefit but bempedoic acid is not a substitute for a properly conducted statin rechallenge in a patient who has not completed the protocol.
Option C: Option C is incorrect — the clinical presentation described (diffuse myalgia during three weeks of high-dose statin, self-limited after discontinuation, no CK elevation documented) is not consistent with statin-associated autoimmune myopathy, which is characterized by progressive worsening after discontinuation and markedly elevated CK; anti-HMGCR testing is not indicated here, and rechallenge is not contraindicated.
Option D: Option D is incorrect — PCSK9 inhibitors have demonstrated cardiovascular event reduction in patients with established ASCVD and are approved for use in statin-intolerant patients, but they are not first-line ahead of completing a structured statin rechallenge protocol in a patient who has not genuinely confirmed intolerance; they are best used as adjuncts to maximum tolerated statin therapy.
Option E: Option E is incorrect — rechallenging with the identical statin at the identical dose that triggered symptoms is not required by any guideline rechallenge protocol; switching to a different statin at a lower dose is the appropriate first rechallenge step and reduces the risk of symptom recurrence due to statin-specific factors.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.